title: Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.
abstract: Priming with a live recombinant vector followed by subunit boosting is a promising strategy for human immunodeficiency virus (HIV) immunization. Twenty-nine vaccinia-naive volunteers were primed with gp160-recombinant vaccinia virus (HIVAC-1e) and boosted with recombinant (r) gp160 to define factors associated with the magnitude and specificity of antibody response after booster immunization. A longer interval between inoculation and boost, two inoculations of HIVAC-1e with lesion formation occurring after the first, and Western blot-detectable antibody to gp160 after inoculation were significantly associated with higher neutralizing antibody titers and fusion-inhibiting activity after boosting. HIVAC-1e-primed vaccinees were more likely to have antibody to V3- and CD4-binding regions of gp120 and less likely to have antibody to constant regions 2 and 3 than vaccinees immunized with rgp160 alone. Priming volunteers with HIVAC-1e was a key determinant of the epitope specificity and magnitude of functional antibody responses induced by rgp160 boosting.
authors.affiliation: Dept. of Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232.
authors.forename: B S
authors.initials: BS
authors.lastname: Graham
authors.forename: G J
authors.initials: GJ
authors.lastname: Gorse
authors.forename: D H
authors.initials: DH
authors.lastname: Schwartz
authors.forename: M C
authors.initials: MC
authors.lastname: Keefer
authors.forename: M J
authors.initials: MJ
authors.lastname: McElrath
authors.forename: T J
authors.initials: TJ
authors.lastname: Matthews
authors.forename: P F
authors.initials: PF
authors.lastname: Wright
authors.forename: R B
authors.initials: RB
authors.lastname: Belshe
authors.forename: M L
authors.initials: ML
authors.lastname: Clements
authors.forename: R
authors.initials: R
authors.lastname: Dolin
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D000328:Adult; D000917:Antibody Formation; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D015686:Gene Products, env / Q000276:immunology*; D019302:HIV Envelope Protein gp160; D018023:HIV Seronegativity / Q000276:immunology; D006801:Humans; D007117:Immunization, Secondary; D008875:Middle Aged; D011498:Protein Precursors / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D016915:AIDS Vaccines; D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; D011498:Protein Precursors; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines